Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 ...

09:30 EST AbbVie (ABBV) seeing ‘significant advancements’ across entire pipeline Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now ...

(RTTNews) - Below are the earnings highlights for AbbVie (ABBV): Earnings: -$22 million in Q4 vs. $822 million in the same period last year. EPS: -$0.02 in Q4 vs. $0.46 in the same period last year.

Researchers found that isolated exercise, isolated nutritional, and combined exercise, nutrition, plus psychosocial prehabilitation were most likely to reduce complications compared with standard ...

NEW YORK & COPENHAGEN - Pfizer Inc. (NYSE: NYSE:PFE) and Genmab A/S (NASDAQ: NASDAQ:GMAB) have received full approval from the U.S. Food and Drug Administration (FDA) for... On Friday, the stock ...

Of course, like all wardrobe basics, there are several tiers of quality and prices for sweatshirts. You have your more affordable crewnecks, staples like Champion, H&M, and Russell, which fans ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a 26.5 million euros ($27.7 million) oversubscribed Series A financing from a broad ...

The ORR was 70% in patients treated with remestemcel-L, with 30% having a complete response and 41% having a partial response. The Food and Drug Administration (FDA) has approved Ryoncil ...